Absenteeism in Remission: Planning, Policy, Culture

It has been estimated that employee absenteeism costs the U.S. economy on the order of $40 billion per year. Not surprisingly, great time and effort has been dedicated to research assessing the causes of employee absenteeism with the obvious goal of reducing its incidence in the workplace. It is argued in this article that much of this effort has been of virtually no practical value to the practicing manager. In fact, the prescriptions that would naturally arise from much of this research would almost certainly land managers in the lap of litigation in federal court. Two promising strategies —attention to absence policy and absence culture—are described in this article. Both have the advantage of practical application as well as a distinguished tradition in reducing absenteeism

New Directions in the Management of Employee Absenteeism: Attention to Policy and Culture

[Excerpt] Over one million American workers who are otherwise employed will not attend work on any given day: they will be absent. Given the expense and disruption associated with such widespread employee absenteeism, it will come as no surprise that a great deal of time has been spent to determine the causes of employee absenteeism and how its incidence might be reduced. Sadly, however, it has been concluded that the heavy investment of research effort on absenteeism has failed to generate significant dividends, whether one’s criterion is the prediction, explanation, or control of absence (Chadwick-Jones, Nicholson, & Brown, 1982). While prior absence research has not and does not serve the practicing manager very well, new research on employee absenteeism provides promising avenues for management. This chapter will provide an overview of the magnitude of the absenteeism problem and a rationale for why much of the earlier study of workplace absenteeism did not, as a practical matter, provide much information or direction to managers. Then the new directions in the management of absenteeism” will be examined

Goal: 5000-7500 words Currently: 6,465 words (including everything) Exclusive Dealing: Before Bork, and Beyond

Abstract: Antitrust scholars have come to accept the basic ideas about exclusive dealing that Bork articulated in The Antitrust Paradox. Indeed, they have even extended his list of reasons why exclusive dealing can promote economic efficiency. Yet they have also taken up his challenge to explain how exclusive dealing could possibly cause harm, and have modelled a variety of special cases where it does. Some (albeit not all) of these are sufficiently plausible to be useful to prosecutors and judges

Confidential Gossip and Organization Studies

This essay sets out the case for regarding confidential gossip as a significant concept in the study of organizations. It develops the more general concept of gossip by combining it with concepts of organizational secrecy in order to propose confidential gossip as a distinctive communicative practice. As a communicative practice, it is to be understood as playing a particular role within the communicative constitution of organizations. That particularity arises from the special nature of any communication regarded as secret, which includes the fact that such communication is liable to be regarded as containing the ‘real truth’ or ‘insider knowledge’. Thus it may be regarded as more than ‘just gossip’ and also as more significant than formal communication. This role is explored, as well as the methodological and ethical challenges of studying confidential gossip empirically

Operation Moonshot: rapid translation of a SARS-CoV-2 targeted peptide immunoaffinity liquid chromatography-tandem mass spectrometry test from research into routine clinical use

OBJECTIVES: During 2020, the UK's Department of Health and Social Care (DHSC) established the Moonshot programme to fund various diagnostic approaches for the detection of SARS-CoV-2, the pathogen behind the COVID-19 pandemic. Mass spectrometry was one of the technologies proposed to increase testing capacity. METHODS: Moonshot funded a multi-phase development programme, bringing together experts from academia, industry and the NHS to develop a state-of-the-art targeted protein assay utilising enrichment and liquid chromatography tandem mass spectrometry (LC-MS/MS) to capture and detect low levels of tryptic peptides derived from SARS-CoV-2 virus. The assay relies on detection of target peptides, ADETQALPQRK (ADE) and AYNVTQAFGR (AYN), derived from the nucleocapsid protein of SARS-CoV-2, measurement of which allowed the specific, sensitive, and robust detection of the virus from nasopharyngeal (NP) swabs. The diagnostic sensitivity and specificity of LC-MS/MS was compared with reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) via a prospective study. RESULTS: Analysis of NP swabs (n=361) with a median RT-qPCR quantification cycle (Cq) of 27 (range 16.7-39.1) demonstrated diagnostic sensitivity of 92.4% (87.4-95.5), specificity of 97.4% (94.0-98.9) and near total concordance with RT-qPCR (Cohen's Kappa 0.90). Excluding Cq>32 samples, sensitivity was 97.9% (94.1-99.3), specificity 97.4% (94.0-98.9) and Cohen's Kappa 0.95. CONCLUSIONS: This unique collaboration between academia, industry and the NHS enabled development, translation, and validation of a SARS-CoV-2 method in NP swabs to be achieved in 5 months. This pilot provides a model and pipeline for future accelerated development and implementation of LC-MS/MS protein/peptide assays into the routine clinical laboratory

Composition of the Top Management Team and Firm International Diversification

This study investigates the impact of various top management team characteristics on firm international diversification. Relying on data from 126 firms in the electronics industry, we find that certain top management team characteristics are related to international expansion. Specifically, results indicate that lower average age, higher average tenure, higher average elite education, higher average international experience, and higher tenure heterogeneity are associated with firm international diversification. The study reinforces the importance of top management team composition in internationalization decisions and suggests further research in this context.Yeshttps://us.sagepub.com/en-us/nam/manuscript-submission-guideline

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049